Search

Learn how one man's determination to be a doctor took him on an incredible journey from working at a car wash in the Bronx to becoming a physician at Memorial Sloan Kettering Cancer Center, with the help of mentors and a world-class work ethic.

… Wednesday, November 3, 2021 Man in surgical scrubs looks at reader Aymar Borel Soh Fotso (Dr. Soh) is an anesthesiologist at Memorial Sloan Kettering Cancer Center. Scroll right for more photos » Borel Soh, Louis Voigt, and Kathryn Martin Dr. Soh (left) at a gala with two of his MSK mentors, Louis Voigt

Gerstner Sloan Kettering student Jessica Rios-Esteves has been awarded the Chairman’s Prize for her first-author paper published in Cell Reports in 2013.

… Wednesday, August 13, 2014 Gerstner Sloan Kettering student Jessica Rios-Esteves has been awarded the Chairman’s Prize for her first-author paper Stearoyl CoA Desaturase Is  Required to Produce Active, Lipid-Modified Wnt Proteins , published in Cell Reports in 2013. Jessica successfully defended her

Learn more about how MSK helps international patients like Annabel Gutherz, a 25-year-old singer from Montreal who sought MSK's expertise in head and neck cancer and found comfort and support far from home.

… Monday, April 7, 2025 There are good reasons for optimism today when the diagnosis is thyroid cancer. At Memorial Sloan Kettering Cancer Center (MSK), most  thyroid cancer treatments — which can include surgery, drugs, or both — are successful, and the overall  survival rates are more than 95%. But when

Memorial Sloan Kettering researchers have discovered that the AR and PI3K disease pathways regulate each other through reciprocal negative feedback.

… Friday, July 1, 2011 Summary Memorial Sloan Kettering researchers have discovered that the AR and PI3K disease pathways regulate each other through reciprocal negative feedback. Prostate cancer is difficult to control once it spreads beyond the initial tumor to other parts of the body. The standard treatment

Detecting a protein in a blood sample could help doctors make treatment decisions for prostate cancer patients.

… Friday, June 29, 2018 Summary A study shows that a blood test that detects a protein called AR-V7 in circulating tumor cells accurately predicts how well certain people with prostate cancer will respond to drugs called AR inhibitors. Doctors can use this test to make decisions about whether these patients

A recent study holds promise for the development of a new type of drug to alleviate immune deficiency caused by cancer treatment, radiation injury, or certain diseases.

… Friday, April 6, 2012 Summary A recent study holds promise for the development of a new type of drug to alleviate immune deficiency caused by cancer treatment, radiation injury, or certain diseases. Some cancer treatments — including bone marrow transplantation , chemotherapy, and radiation — can temporarily

A new laboratory study provides evidence about how advanced age can be protective against cancer — with implications for treating patients in different age groups.

… Wednesday, December 4, 2024 When it comes to cancer, aging is a double-edged sword, researchers are increasingly learning. Age is considered the most important risk factor for cancer . That’s because genetic mutations build up in cells over years and decades, and ultimately drive the development of cancer

A study of nearly 900 kidney cancer tumors has identified previously unknown biomarkers that correlate with better treatment responses to immunotherapy and targeted therapy.

… Monday, September 7, 2020 Summary An international team of investigators led by Memorial Sloan Kettering’s Robert Motzer has identified biological attributes of kidney cancer tumors that correlate with better responses to immunotherapies and targeted therapies. Treatments for kidney cancer have improved

On December 4, 2024, the U.S. Food and Drug Administration granted accelerated approval to zenocutuzumab (Bizengri®), the first approved systemic therapy for patients with advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) fusion and pancreatic adenocarcinoma harboring a (NRG1) fusion.

… Thursday, February 6, 2025 Zenocutuzumab is a novel bispecific antibody designed by Merus, N.V. In a multicenter global phase 2 clinical trial led by MSK gynecologic medical oncologist and early drug development specialist Alison Schram, MD , the drug demonstrated durable antitumor activity and met prespecified

As we approach the end of 2019, learn about some of the biggest advances in clinical research made this year at MSK.

… Thursday, December 12, 2019 In 2019, MSK clinical researchers made several major discoveries that will improve the treatment of cancer and guide the development of new therapies. Many of these studies were made possible by large and small philanthropic donations, which allow researchers to pursue innovative